Juneflecad Laboratorios Liconsa, S.A. (Flecainide Acetate)

Flecainide works by selectively blocking fast inward sodium channels in heart muscle cells. This inhibition reduces the rapid depolarization phase of the cardiac action potential, slowing conduction velocity and prolonging the refractory period, which helps to stabilize abnormal electrical activity and restore a regular heartbeat.

The dose of Flecainide is individualized by the prescribing clinician based on factors such as the specific arrhythmia being treated, the patient’s age, weight, renal function, and response to therapy. Dosage adjustments are made according to therapeutic monitoring and clinical judgment, not by a fixed regimen.

Safety data for Flecainide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the uncertainties with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Juneflecad. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Flecainide is a Class Ic agent that primarily blocks sodium channels, offering rapid onset and precise control of certain arrhythmias. Amiodarone, a Class III drug, has broader electrophysiological effects and is often used for a wider range of rhythm disorders but carries a higher risk of long‑term organ toxicity. Choice depends on the clinical scenario, comorbidities and safety profile.

Juneflecad should be stored at temperatures below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain stability and potency.

Juneflecad is administered orally, typically as a tablet or capsule taken with or without food as directed by the prescriber. The exact dosing schedule and duration are individualized based on the patient’s condition, response to therapy and any concurrent medications.

The most serious risks include proarrhythmia (new or worsening arrhythmias), severe heart block, and marked hypotension. Patients should be monitored closely for signs of these events, especially during initiation or dose changes, and any symptoms such as fainting, palpitations or chest discomfort should prompt immediate medical evaluation.

Flecainide is contraindicated in patients with known structural heart disease, recent myocardial infarction, severe heart failure, or significant conduction system disease. It should also be avoided in individuals taking other Class I antiarrhythmics or drugs that markedly prolong the QT interval, unless a specialist determines that benefits outweigh the risks.